Mutual of America Capital Management LLC Has $3.55 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Mutual of America Capital Management LLC lowered its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 0.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 39,522 shares of the company’s stock after selling 371 shares during the quarter. Mutual of America Capital Management LLC owned about 0.08% of Axsome Therapeutics worth $3,552,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in AXSM. Vanguard Group Inc. boosted its holdings in Axsome Therapeutics by 1.2% during the first quarter. Vanguard Group Inc. now owns 3,740,278 shares of the company’s stock worth $298,474,000 after buying an additional 43,512 shares during the last quarter. Bellevue Group AG grew its holdings in Axsome Therapeutics by 7.9% during the first quarter. Bellevue Group AG now owns 685,476 shares of the company’s stock valued at $54,701,000 after purchasing an additional 50,104 shares during the period. XTX Topco Ltd grew its holdings in Axsome Therapeutics by 177.9% during the second quarter. XTX Topco Ltd now owns 11,205 shares of the company’s stock valued at $902,000 after purchasing an additional 7,173 shares during the period. Tri Locum Partners LP increased its stake in Axsome Therapeutics by 198.4% in the second quarter. Tri Locum Partners LP now owns 306,513 shares of the company’s stock valued at $24,674,000 after purchasing an additional 203,802 shares in the last quarter. Finally, Sofinnova Investments Inc. acquired a new stake in Axsome Therapeutics in the second quarter worth $24,971,000. 81.49% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Wells Fargo & Company assumed coverage on shares of Axsome Therapeutics in a research report on Tuesday, September 3rd. They issued an “overweight” rating and a $140.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $130.00 price target on shares of Axsome Therapeutics in a research report on Tuesday, November 12th. Bank of America upgraded Axsome Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $95.00 to $106.00 in a report on Tuesday, August 6th. UBS Group lowered their target price on Axsome Therapeutics from $107.00 to $105.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Finally, StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $124.93.

Axsome Therapeutics Price Performance

Shares of NASDAQ AXSM opened at $98.68 on Friday. Axsome Therapeutics, Inc. has a fifty-two week low of $60.28 and a fifty-two week high of $105.00. The stock has a market capitalization of $4.78 billion, a price-to-earnings ratio of -15.04 and a beta of 1.26. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The business has a 50-day moving average of $90.89 and a 200-day moving average of $84.85.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. The firm had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same quarter in the previous year, the firm earned ($1.32) EPS. As a group, sell-side analysts predict that Axsome Therapeutics, Inc. will post -4.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Mark E. Saad sold 11,016 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the transaction, the director now directly owns 10,002 shares in the company, valued at $913,282.62. The trade was a 52.41 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 22.40% of the company’s stock.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.